Jump to content
RemedySpot.com

New Rapid Lyme test

Rate this topic


Guest guest

Recommended Posts

Guest guest

FYI

===================================

Wampole Laboratories Launches First Rapid Test for Lyme Disease

CRANBURY, N.J.--(BUSINESS WIRE)--June 21, 1999--Wampole Laboratories, a

division of -Wallace, Inc. (NYSE:CAR) today announced that the

PreVue B. burgdorferi Antibody Detection Assay, the first rapid test for

Lyme disease, is now available. The launch of the PreVue B. burgdorferi test

comes at the peak of Lyme season, which for most endemic areas occurs in late

spring and summer. The PreVue product is being sold to physician offices and

clinical laboratories by Wampole Laboratories through a network of authorized

distributors.

The Wampole PreVue B. burgdorferi assay is a simple two-step rapid

membrane test which provides visually-read color results using serum or whole

blood samples, including fingerstick blood. The test can be used in physician

offices and other point of care settings and provides results in 20 minutes,

as opposed to standard laboratory tests, which can take up to a week. Using

the Wampole PreVue assay, physicians will be able to make a probable

diagnosis of Lyme disease while the patient is present, and make antibiotic

treatment decisions immediately.

The Wampole PreVue B. burgdorferi test utilizes unique recombinant

antigens rather than the whole cell preparations used in current laboratory

tests. Antigenic proteins developed by recombinant DNA techniques allow for

greater accuracy than other methods. In clinical studies, the Wampole PreVue

B. burgdorferi assay demonstrated excellent performance in comparison to

Western Blot and ELISA test methods on a CDC Lyme Disease stratified panel

(95.2% agreement for Wampole PreVue versus 78.6% for Western Blot and 85.7%

for ELISA).

Ms. Zych, Vice President of Marketing for Wampole Laboratories

provided the following comment: " The market reaction to the PreVue B.

burgdorferi test has been tremendous. Not only does the recombinant

technology provide greater accuracy, the test's speed and simplicity allows

it to be performed in the physician's office while the patient waits for the

results. This not only allows for more rapid treatment decisions, which

improves the patient's outcome, but it also reduces patient anxiety over

waiting up to a week for test results. "

Luft M.D., Chairman of the Department of Medicine at SUNY,

Stony Brook, where the PreVue test's core technology was developed, added the

following: " This technology will allow both a rapid and more specific

diagnosis of Lyme disease. A rapid diagnosis will allow prompt initiation of

appropriate therapy, which is probably the most important factor in curing

this disease. "

Lyme disease is the most common insect-borne infectious disease in North

America and is a significant public health concern. Spread to humans

primarily by tick bite, its causative agent is the spirochete Borrelia

burgdorferi. Clinical manifestations of Lyme disease include a large

bulls-eye rash, followed by flu-like symptoms, fatigue and joint pain.

Diagnosis can be a challenge because many symptoms are similar to other

conditions. Borrelia burgdorferi antibody tests such as the Wampole PreVue

assay are a critical component in diagnosing Lyme disease.

Wampole Laboratories is a market leader in Lyme disease testing and the

PreVue B. burgdorferi test expands their presence into the point-of care

segment of this market. Wampole is working on the development of additional

recombinant-based Lyme tests that will be useful in patients who have been

vaccinated against Lyme disease. The work is being done in conjunction with

scientists at Brook Biotechnologies and SUNY Stony Brook, where the PreVue B.

burgdorferi product's core technology was developed.

CONTACT:

Wampole Labs, Cranbury

P. Zych

Vice President of Marketing

609/655-6587

To edit your profile, go to keyword <A

HREF= " aol://1722:NewsProfiles " >NewsProfiles

</A>.

For all of today's news, go to keyword <A HREF= " aol://1722:News " >News</A>

Link to comment
Share on other sites

Guest guest

this is old news....came out about 4 months ago.....they claimed a 90%

accuracy rate.......if regular testing is only 30% how will a " fast test " be

any better???????

Reid

Link to comment
Share on other sites

Guest guest

In a message dated 6/22/1999 2:41:21 PM Eastern Daylight Time,

RMcmur3194@... writes:

<< .came out about 4 months ago. >>

Reid: Check your info......I don't think this is the same test. Mona

Link to comment
Share on other sites

Guest guest

same test same co....was in the paper 4 months ago also on the web.......i

will double check though.......still a quick test when they can't sdo it

right by taking time....???????guess i am skeptical by nature.......

Reid

Link to comment
Share on other sites

Guest guest

What test is this?

My ISP has been down and I'm not getting all ofthe posts - can someone tell

me who is the company , a way to contact them and what is the name of the

test???? Is it really that much more accurate ????

Jaqui

Re: [ ] New Rapid Lyme test

>From: RMcmur3194@...

>

>this is old news....came out about 4 months ago.....they claimed a 90%

>accuracy rate.......if regular testing is only 30% how will a " fast test "

be

>any better???????

>Reid

>

>---------------------------

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...